CTLA4 and melanoma: In 2011, Ipilimumab, a monoclonal antibody (mAb) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), became the first ICI approved by the U.S. Food and Drug Administration (FDA) for treating advanced melanoma (Mansh, 2011).